Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients

By WebmasterJuly 7, 2020November 1st, 2024No Comments

Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients

Previous PostRelmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
Next PostRide Health Expands Transportation Services to Support Hospitals and Health Plans Through COVID-19 Challenges